Switching biologic treatment for patients with moderate to severe psoriasis, needn't be daunting, Vender said; he works through a tricky case that ended very well.

Dermatology experts share pearls to help when biologics alone are not enough, when obesity is a comorbidity with psoriasis, and when isotype switching derails therapy.

Insights include new data on combination therapies, topical antiandrogens, and innovative retinoid formulations.

JAK inhibitors are being used widely and successfully to treat alopecia areata, and Amy McMichaels, MD, showcased data and also discussed patient communication.

There really is no debate - it's all about individualizing treatment for the patient, but Drs Neal Bhatia and Raj Chovatiya went head to head at Midwinter Hawaii.

April Armstrong, MD, discussed the latest data on apremilast, deucravacitinib, and emerging TYK2 and IL-23 inhibitors at Midwinter Hawaii.

The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.

The 2025 Winter Clinical Hawaii kicks off today with the first full day of educational sessions starting tomorrow, February 15 - here's what to look for.

The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.

The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.

ADA 2024. Adults started on the Omnipod 5 AID system had an A1c reduction from 8.2% at baseline to 7.4% at 13 weeks, researchers report.

ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.

ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.